Cargando…
Screening for MAFLD: who, when and how?
Metabolic-associated fatty liver disease (MAFLD) is a highly prevalent disease with increasing prevalence worldwide. Currently, no universal screening methods have been standardized, even when this disease poses a major health burden. MAFLD as a spectrum of diseases can range from simple steatosis,...
Autores principales: | Pal, Shreya C., Méndez-Sánchez, Nahum |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9869195/ https://www.ncbi.nlm.nih.gov/pubmed/36699945 http://dx.doi.org/10.1177/20420188221145650 |
Ejemplares similares
-
MAFLD: a multisystem disease
por: Pipitone, Rosaria Maria, et al.
Publicado: (2023) -
Emerging pharmacological treatment options for MAFLD
por: Rojas, Ángela, et al.
Publicado: (2022) -
Should we undertake surveillance for HCC in patients with MAFLD?
por: Norero, Blanca, et al.
Publicado: (2023) -
Non-pharmacological management options for MAFLD: a practical
guide
por: Stefano, José Tadeu, et al.
Publicado: (2023) -
The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease
por: Kulkarni, Anand V., et al.
Publicado: (2023)